2020年《系统性硬化症和COVID-19大流行：世界硬皮病基金会对患者管理的初步建议》解读

doi:10.12114/j.issn.1007-9572.2021.00.445

摘要/Abstract

摘要： 新型冠状病毒肺炎（COVID-19）仍在世界范围内流行，系统性硬化症（SSc）患者因常继发间质性肺疾病且广泛使用激素及免疫抑制剂而在疫情期间应受到关注，其一旦感染则面临着疾病恶化甚至死亡的风险。因此世界硬皮病基金会（WSF）针对COVID-19大流行提出了SSc患者的管理建议，本文通过对该建议进行解读与评析，对目前SSc合并COVID-19治疗手段进行了总结与展望，为SSc患者在COVID-19大流行下的临床治疗提供参考。

关键词: 硬皮病, 系统性；新型冠状病毒肺炎；系统性硬化症；间质性肺疾病；治疗

Abstract: Currently，COVID-19 continues to overwhelmingly hit almost all the countries of the world．It is noteworthy that patients with systemic sclerosis are considered to be a group at risk for disease deterioration and even death when they get infected COVID-19 due to the co-morbidity of interstitial lung disease and widespread use of glucocorticoids and immunosuppressive agents．In this case，the World Scleroderma Foundation put forward recommendations for the management of patients with SSc．We introduced and interpreted these recommendations，with a summary of present treatment strategies for SSc patients with COVID-19，aiming to provide more options for clinical management of these patients．
Scleroderma，systemic；COVID-19；Systemic sclerosis；Interstitial lung disease；Treatment

崔洁涵,杨林,汪晓平,等. 2020年《系统性硬化症和COVID-19大流行：世界硬皮病基金会对患者管理的初步建议》解读[J]. 中国全科医学, 2021, 24(17): 2218-2223. DOI: 10.12114/j.issn.1007-9572.2021.00.445.
CUI Jiehan,YANG Lin,WANG Xiaoping, et al. Interpretation of Systemic Sclerosis and the COVID-19 Pandemic：World Scleroderma Foundation Preliminary Advice for Patient Management　[J]. Chinese General Practice, 2021, 24(17): 2218-2223. DOI: 10.12114/j.issn.1007-9572.2021.00.445.

参考文献

［1］HUANG C L，WANG Y M，LI X W，et al．Clinical features of patients infected with 2019 novel coronavirus in Wuhan，China［J］．Lancet，2020，395（10223）：497-506．DOI：10.1016/S0140-6736（20）30183-5．
［2］Coronaviridae Study Group of the International Committee on Taxonomy of Viruses．The species severe acute respiratory syndrome-related coronavirus：classifying 2019-nCoV and naming it SARS-CoV-2［J］．Nat Microbiol，2020，5（4）：536-544．DOI：10.1038/s41564-020-0695-z．
［3］DENTON C P，KHANNA D．Systemic sclerosis［J］．Lancet，2017，390（10103）：1685-1699．DOI：10.1016/S0140-6736（17）30933-9．
［4］MATUCCI-CERINIC M，BRUNI C，ALLANORE Y，et al．Systemic sclerosis and the COVID-19 pandemic：World Scleroderma Foundation preliminary advice for patient management［J］．Ann Rheum Dis，2020，79（6）：724-726．DOI：10.1136/annrheumdis-2020-217407．
［5］KOWAL-BIELECKA O，FRANSEN J，AVOUAC J，et al．Update of EULAR recommendations for the treatment of systemic sclerosis［J］．Ann Rheum Dis，2017，76（8）：1327-1339． DOI：10.1136/annrheumdis-2016-209909．
［6］MEHTA P，MCAULEY D F，BROWN M，et al．COVID-19：consider cytokine storm syndromes and immunosuppression［J］．Lancet，2020，395（10229）：1033-1034．DOI：10.1016/S0140-6736（20）30628-0．
［7］D&APOS，ANTIGA L．Coronaviruses and immunosuppressed patients：the facts during the third epidemic［J］．Liver Transpl，2020，26（6）：832-834．DOI：10.1002/lt.25756．
［8］国家卫生健康委疾控局．《公民防疫行为准则》（科普版）［EB/OL］（2020-10-14）［2021-01-14］．http：//www.nhc.gov.cn/jkj/s7934td/202010/eaef96a9c09a4650ba54536c0c0ed9ce.shtml．
［9］MIHAI C，DOBROTA R，SCHRÖDER M，et al．COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD［J］．Ann Rheum Dis，2020，79（5）：668-669．DOI：10.1136/annrheumdis-2020-217442．
［10］LI G D，DE CLERCQ E．Therapeutic options for the 2019 novel coronavirus（2019-nCoV）［J］． Nat Rev Drug Discov，2020，19（3）：149-150．DOI：10.1038/d41573-020-00016-0．
［11］ZUMLA A，CHAN J F，AZHAR E I，et al．Coronaviruses-drug discovery and therapeutic options［J］．Nat Rev Drug Discov，2016，15（5）：327-347． DOI：10.1038/nrd.2015.37．
［12］MORSE J S，LALONDE T，XU S Q，et al．Learning from the past：possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV［J］．ChemBioChem，2020，21（5）：730-738．DOI：10.1002/cbic.202000047．
［13］DE CLERCQ E．New nucleoside analogues for the treatment of hemorrhagic fever virus infections［J］．Chem Asian J，2019，14（22）：39．
［14］中华人民共和国国家卫生健康委员会办公厅，国家中医药管理局办公室．新型冠状病毒肺炎诊疗方案（试行第八版）［J］．中国医药，2020，10：1494-1499．http：//d.wanfangdata.com.cn/periodical/zhongguoyy202010002．
［15］DE WIT E，FELDMANN F，CRONIN J，et al．Prophylactic and therapeutic remdesivir（GS-5734） treatment in the rhesus macaque model of MERS-CoV infection［J］．Proc Natl Acad Sci USA，2020，117（12）：6771-6776．DOI：10.1073/pnas.1922083117．
［16］TEJERO H，MONTERO F，NUÑO J C．Theories of lethal mutagenesis：from error catastrophe to lethal defection［J］．Curr Top Microbiol Immunol，2016，392：161-179．DOI：10.1007/82_2015_463．
［17］SHEAHAN T P，SIMS A C，GRAHAM R L，et al．Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses［J］．Sci Transl Med，2017，9（396）：eaal3653．DOI：10.1126/scitranslmed.aal3653．
［18］HOLSHUE M L，DEBOLT C，LINDQUIST S，et al．First case of 2019 novel coronavirus in the United States［J］．N Engl J Med，2020，382（10）：929-936．DOI：10.1056/NEJMoa2001191．
［19］BEIGEL J H，TOMASHEK K M，DODD L E，et al．Remdesivir for the treatment of COVID-19-final report［J］．N Engl J Med，2020，383（19）：1813-1826．DOI：10.1056/NEJMoa2007764．
［20］WANG Y M，ZHANG D Y，DU G H，et al．Remdesivir in adults with severe COVID-19：a randomised，double-blind，placebo-controlled，multicentre trial［J］．Lancet，2020，395（10236）：1569-1578．DOI：10.1016/S0140-6736（20）31022-9．
［21］HUNG I F，LUNG K C，TSO E Y，et al．Triple combination of interferon beta-1b，lopinavir-ritonavir，and ribavirin in the treatment of patients admitted to hospital with COVID-19：an open-label，randomised，phase 2 trial［J］．Lancet，2020，395（10238）：1695-1704．DOI：10.1016/S0140-6736（20）31042-4．
［22］CAO B，WANG Y M，WEN D N，et al．A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19［J］．N Engl J Med，2020，382（19）：1787-1799．DOI：10.1056/NEJMoa2001282．
［23］AVOUAC J，AIRÓ P，CARLIER N，et al．Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab［J］．Ann Rheum Dis，2020：annrheumdis-annrheu2020-217864．DOI：10.1136/annrheumdis-2020-217864．
［24］NOJOMI M，YASSIN Z，KEYVANI H，et al．Effect of Arbidol（Umifenovir） on COVID-19：a randomized controlled trial［J］．BMC Infect Dis，2020，20（1）：954．DOI：10.1186/s12879-020-05698-w．
［25］SALLARD E，LESCURE F X，YAZDANPANAH Y，et al．Type 1 interferons as a potential treatment against COVID-19［J］．Antiviral Res，2020，178：104791．DOI：10.1016/j.antiviral.2020.104791．
［26］WALZ L，COHEN A J，REBAZA A P，et al．JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients：a systematic review and meta-analysis［J］．BMC Infect Dis，2021，21（1）：47．DOI：10.1186/s12879-020-05730-z．
［27］DAVOUDI-MONFARED E，RAHMANI H，KHALILI H，et al．A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19［J］．Antimicrob Agents Chemother，2020，64（9）：e01061-01020．DOI：10.1128/AAC.01061-20．
［28］RAHMANI H，DAVOUDI-MONFARED E，NOURIAN A，et al．Interferon β-1b in treatment of severe COVID-19：a randomized clinical trial［J］．Int Immunopharmacol，2020，88：106903．DOI：10.1016/j.intimp.2020.106903．
［29］DELANEY T A，MOREHOUSE C，BROHAWN P Z，et al．Type I IFNs regulate inflammation，vasculopathy，and fibrosis in chronic cutaneous graft-versus-host disease［J］．J Immunol，2016，197（1）：42-50．DOI：10.4049/jimmunol.1502190．
［30］SAVARINO A，DI TRANI L，DONATELLI I，et al．New insights into the antiviral effects of chloroquine［J］．Lancet Infect Dis，2006，6（2）：67-69．DOI：10.1016/S1473-3099（06）70361-9．
［31］WANG M L，CAO R Y，ZHANG L K，et al．Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus（2019-nCoV） in vitro［J］．Cell Res，2020，30（3）：269-271．DOI：10.1038/s41422-020-0282-0．
［32］JANG C H，CHOI J H，BYUN M S，et al．Chloroquine inhibits production of TNF-alpha，IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes［J］．Rheumatology（Oxford），2006，45（6）：703-710．DOI：10.1093/rheumatology/kei282．
［33］EKTORP E．Death threats after a trial on chloroquine for COVID-19［J］．Lancet Infect Dis，2020，20（6）：661．DOI：10.1016/s1473-3099（20）30383-2．
［34］SELF W H，SEMLER M W，LEITHER L M，et al．Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19：a randomized clinical trial［J］．JAMA，2020，324（21）：2165-2176．DOI：10.1001/jama.2020.22240．
［35］GROUP R C，HORBY P，MAFHAM M，et al．Effect of hydroxychloroquine in hospitalized patients with covid-19［J］．N Engl J Med，2020，383（21）：2030-2040．DOI：10.1056/NEJMoa2022926．
［36］XU X L，HAN M F，LI T T，et al．Effective treatment of severe COVID-19 patients with tocilizumab［J］．Proc Natl Acad Sci USA，2020，117（20）：10970-10975．DOI：10.1073/pnas.2005615117．
［37］COPAESCU A，SMIBERT O，GIBSON A，et al．The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection［J］．J Allergy Clin Immunol，2020，146（3）：518-534.e1．DOI：10.1016/j.jaci.2020.07.001．
［38］CHEN G，WU D，GUO W，et al．Clinical and immunological features of severe and moderate coronavirus disease 2019［J］．J Clin Invest，2020，130（5）：2620-2629．DOI：10.1172/JCI137244．
［39］JIN Y H，CAI L，CHENG Z S，et al．A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus（2019-nCoV） infected pneumonia（standard version）［J］．Mil Med Res，2020，7（1）：4．DOI：10.1186/s40779-020-0233-6．
［40］LESCOAT A，LELONG M，JELJELI M，et al．Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo：perspectives for scleroderma-associated interstitial lung disease［J］．Biochem Pharmacol，2020，178：114103．DOI：10.1016/j.bcp.2020.114103．
［41］RICARD L，JACHIET V，MALARD F，et al．Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib［J］．Ann Rheum Dis，2019，78（4）：539-550．DOI：10.1136/annrheumdis-2018-214382．
［42］GOZZETTI A，CAPOCHIANI E，BOCCHIA M．The janus kinase 1/2 inhibitor ruxolitinib in COVID-19［J］．Leukemia，2020，34（10）：2815-2816．DOI：10.1038/s41375-020-01038-8．
［43］REYNOLDS H R，ADHIKARI S，PULGARIN C，et al．Renin-angiotensin-aldosterone system inhibitors and risk of covid-19［J］．N Engl J Med，2020，382（25）：2441-2448．DOI：10.1056/NEJMoa2008975．
［44］ZHANG G Y，WU Y，XU R，et al．Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19：a meta-analysis［J］．J Med Virol，2020．DOI：10.1002/jmv.26695．
［45］PIROLA C J，SOOKOIAN S．Estimation of renin-angiotensin-aldosterone-system（RAAS）-inhibitor effect on COVID-19 outcome：a Meta-analysis［J］．J Infect，2020，81（2）：276-281．DOI：10.1016/j.jinf.2020.05.052．
［46］RUSSELL C D，MILLAR J E，BAILLIE J K．Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury［J］．Lancet，2020，395（10223）：473-475．DOI：10.1016/S0140-6736（20）30317-2．
［47］ZHANG Y，XIAO M，ZHANG S L，et al．Coagulopathy and antiphospholipid antibodies in patients with covid-19［J］．N Engl J Med，2020，382（17）：e38．DOI：10.1056/NEJMc2007575．
［48］ZHOU F，YU T，DU R H，et al．Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan，China：a retrospective cohort study［J］．Lancet，2020，395（10229）：1054-1062．DOI：10.1016/S0140-6736（20）30566-3．
［49］LI T，LU H，ZHANG W．Clinical observation and management of COVID-19 patients［J］．Emerg Microbes Infect，2020，9（1）：687-690．DOI：10.1080/22221751.2020.1741327．
［50］WANG Y，CHEN X D，CAO W，et al．Plasticity of mesenchymal stem cells in immunomodulation：pathological and therapeutic implications［J］．Nat Immunol，2014，15（11）：1009-1016．DOI：10.1038/ni.3002．
［51］NAJAR M，RAICEVIC G，FAYYAD-KAZAN H，et al．Immune-related antigens，surface molecules and regulatory factors in human-derived mesenchymal stromal cells：the expression and impact of inflammatory priming［J］．Stem Cell Rev Rep，2012，8（4）：1188-1198．DOI：10.1007/s12015-012-9408-1．
［52］LENG Z K，ZHU R J，HOU W，et al．Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia［J］．Aging Dis，2020，11（2）：216-228．DOI：10.14336/AD.2020.0228．
［53］LIU S，PENG D Y，QIU H J，et al．Mesenchymal stem cells as a potential therapy for COVID-19［J］．Stem Cell Res Ther，2020，11（1）：169．DOI：10.1186/s13287-020-01678-8．
［54］CHRISTOPEIT M，SCHENDEL M，FÖLL J，et al．Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L［J］．Leukemia，2008，22（5）：1062-1064．DOI：10.1038/sj.leu.2404996．
［55］ROJAS M，RODRÍGUEZ Y，MONSALVE D M，et al．Convalescent plasma in COVID-19：Possible mechanisms of action［J］．Autoimmun Rev，2020，19（7）：102554．DOI：10.1016/j.autrev.2020.102554．
［56］SAHIN U，MUIK A，DERHOVANESSIAN E，et al．COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses［J］．Nature，2020，586（7830）：594-599．DOI：10.1038/s41586-020-2814-7．
［57］XIA S L，DUAN K，ZHANG Y T，et al．Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes：interim analysis of 2 randomized clinical trials［J］．JAMA，2020，324（10）：951-960．DOI：10.1001/jama.2020.15543．
［58］WENDLER D，OCHOA J，MILLUM J，et al．COVID-19 vaccine trial ethics once we have efficacious vaccines［J］．Science，2020，370（6522）：1277-1279．DOI：10.1126/science.abf5084．
［59］NGUYEN T M，ZHANG Y，PANDOLFI P P．Virus against virus：a potential treatment for 2019-nCov（SARS-CoV-2） and other RNA viruses［J］．Cell Res，2020，30：189-190．
［60］ABBOTT T R，DHAMDHERE G，LIU Y X，et al．Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza［J］．Cell，2020，181（4）：865-876.e12．DOI：10.1016/j.cell.2020.04.020．